Major adverse kidney events as an endpoint in acute kidney injury trials: is it time for a RE-MAKE?
作者信息
Fuhrman Dana Y, Bagshaw Sean M, Goldstein Stuart L, Legrand Matthieu, Shaw Andrew D
机构信息
UPMC Children's Hospital of Pittsburgh, 4401 Penn Avenue, Suite 2000, Pittsburgh, PA, 15224, USA.
Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, AB, Canada.
出版信息
Intensive Care Med. 2024 Oct;50(10):1723-1724. doi: 10.1007/s00134-024-07602-5. Epub 2024 Aug 15.
PMID:39145789
Abstract
摘要
相似文献
[1]
Major adverse kidney events as an endpoint in acute kidney injury trials: is it time for a RE-MAKE?
Intensive Care Med. 2024-10
[2]
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology.
Clin J Am Soc Nephrol. 2012-3-22
[3]
Designing clinical trials in acute kidney injury.
Clin J Am Soc Nephrol. 2012-5
[4]
Endpoints for Clinical Trials of Acute Kidney Injury.
Nephron. 2018-9-11
[5]
What can we expect from biomarkers for acute kidney injury?
Biomark Med. 2014
[6]
[7]
AKI-A Relevant Safety End Point?
Am J Kidney Dis. 2020-2-7
[8]
Acute kidney injury biomarkers and endpoints for clinical trials.
Contrib Nephrol. 2011
[9]
[10]
本文引用的文献
[1]
Heterogeneity in the definition of major adverse kidney events: a scoping review.
Intensive Care Med. 2024-7
[3]
[4]
Patient engagement in Canada: a scoping review of the 'how' and 'what' of patient engagement in health research.
Health Res Policy Syst. 2018-2-7
Zotero 插件